Malignant neoplasm of body of stomach
ICD-10 C16.2 is a billable code used to indicate a diagnosis of malignant neoplasm of body of stomach.
C16.2 refers to a malignant neoplasm located specifically in the body of the stomach, which is the central portion of the stomach between the fundus and the pylorus. Gastric cancer, or stomach cancer, is often associated with chronic infection by Helicobacter pylori (H. pylori), a bacterium that can lead to chronic gastritis and is a significant risk factor for the development of gastric adenocarcinoma. The disease typically presents with nonspecific symptoms such as abdominal pain, weight loss, and early satiety, which can complicate early diagnosis. Staging of gastric cancer is crucial for determining treatment options and prognosis, with the TNM classification system being the most widely used. Treatment often involves surgical intervention, such as gastrectomy, which may be total or partial depending on the extent of the disease. Postoperative care and monitoring for recurrence are essential components of management. Accurate coding for C16.2 requires comprehensive documentation of the diagnosis, staging, and treatment plan.
Detailed pathology reports, imaging studies, and treatment plans.
Diagnosis and management of gastric cancer, staging evaluations, and treatment planning.
Ensure accurate documentation of tumor characteristics and treatment response.
Endoscopy reports, biopsy results, and H. pylori testing.
Evaluation of gastric symptoms, management of H. pylori infection, and surveillance for gastric cancer.
Documenting the relationship between H. pylori and gastric cancer risk.
Used for patients with localized gastric cancer requiring surgical intervention.
Operative report detailing the procedure and findings.
Oncologists and surgeons must coordinate documentation for accurate coding.
H. pylori infection is a major risk factor for gastric cancer, as it can lead to chronic inflammation and changes in gastric mucosa that predispose to malignancy.
